Özant HELVACI, Gül Sema KESKİN, Çağlar KESKİN, Çağrı YAYLA, Ülver B. DERİCİ, Özge T. PAŞAOĞLU, Turgay ARINSOY

Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease

Background/aim: We aimed to evaluate the relationship between YKL-40 and endothelial dysfunction in chronic kidney disease.Materials and methods: Twenty-nine hemodialysis patients, 101 patients with nondialytic (stage 2, 3, 4, and 5 ND) chronic kidneydisease (CKD), and 38 healthy individuals as a control group were included. YKL-40 levels were measured by ELISA. Endothelialdysfunction was indirectly measured by flow-mediated dilatation percentage (FMD) in the brachial artery.Results: YKL-40 levels were higher in CKD patients than controls and highest in HD patients (P = 0.001). FMD values were lower innondialytic CKD patients and lowest in HD patients (P = 0.001). YKL-40 negatively correlated with eGFR and FMD values (r = –0.674and r = –0.471, respectively).Conclusion: This study shows that YKL-40 increases with CKD stage and is negatively correlated with FMD measurements.

PDF

___

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
3. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta 2010; 411: 1412-1420.
4. Moody WE, Edwards NC, Madhani M, Chue CD, Steeds RP, Ferro CJ, Townend JN. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 2012; 223: 86-94.
5. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-92
6. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 43: 221-225.
7. Volck B, Price PA, Johansen JS, Sørensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998; 110: 351-360.
8. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, Krause SW. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003; 278: 44058-44067.
9. Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, de Vries CJ. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 687- 694.
10. Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009; 8: 61.
11. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, Nordestgaard BG. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 2009; 27: 572-578.
12. Persson F, Rathcke CN, Gall MA, Parving HH, Vestergaard H, Rossing P. High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 96: 84-89.
13. Okyay GU, Er RE, Tekbudak MY, Paşaoğlu Ö, Inal S, Öneç K, Paşaoğlu H, Altok K, Derici Ü, Erten Y. Novel inflammatory marker in dialysis patients: YKL-40. Ther Apher Dial 2013; 17: 193-201.
14. Mygind ND, Iversen K, Køber L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V et al. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. J Intern Med 2013; 273: 205-216.
15. Tatar E, Gungor O, Celtik A, Sisman AR, Yaprak M, Asci G, Ozkahya M, Toz H. Correlation between serum YKL-40 (chitinase-3-like protein 1) level and proteinuria in renal transplant recipients. Ann Transplant 2013; 18: 95-100.
16. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sørensen O, Price PA. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with communityacquired pneumonia requiring hospitalization. J Infect Dis 1999; 180: 1722-1726.
17. Vos K, Steenbakkers P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hogezand RA, de Vries RR, Breedveld FC, Boots AM. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000; 59: 544-548.
18. Ghanavatian S, Diep LM, Bárány P, Heimbürger O, Seeberger A, Stenvinkel P, Rohani M, Agewall S. Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. Angiology 2014; 65: 443- 449.
19. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.
20. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A et al. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 2011; 26: 3537-3543.
21. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, Yenicesu M, Covic A, Jalal D, Johnson RJ. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 2011; 33: 298-304.
22. Lee JH, Kim SS, Kim IJ, Song SH, Kim YK, In Kim J, Jeon YK, Kim BH, Kwak IS. Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. J Diabetes Complications 2012; 26: 308-312.
23. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010; 26: 150-171.
24. Schernthaner GH, Höbaus C, Brix J. YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease. Anatol J Cardiol 2016; 16: 959.
25. Rusak A, Jabłońska K, Dzięgiel P. The role of YKL-40 in a cancerous process. Postepy Hig Med Dosw (Online) 2016; 70: 1286-1299.
26. Muszyński P, Groblewska M, Kulczyńska-Przybik A, Kułakowska A, Mroczko B. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer’s disease. Curr Neuropharmacol 2017; 15: 906-917.
27. Jafari B, Mohsenin V. Chitinase-3-like protein-1 (YKL-40) as a marker of endothelial dysfunction in obstructive sleep apnea. Sleep Med 2016; 25: 87-92.